The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Nucleic Acid and Oligonucleotide Therapeutics Market Research Report 2024
Synopsis
Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.
The global Nucleic Acid and Oligonucleotide Therapeutics market was valued at US$ 12490 million in 2023 and is anticipated to reach US$ 16120 million by 2030, witnessing a CAGR of 3.7% during the forecast period 2024-2030.
North American market for Nucleic Acid and Oligonucleotide Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Nucleic Acid and Oligonucleotide Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Nucleic Acid and Oligonucleotide Therapeutics in Neuromuscular Diseases is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Nucleic Acid and Oligonucleotide Therapeutics include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Nucleic Acid and Oligonucleotide Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid and Oligonucleotide Therapeutics.
The Nucleic Acid and Oligonucleotide Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Nucleic Acid and Oligonucleotide Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleic Acid and Oligonucleotide Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Segment by Type
Antisense Oligonucleotides (ASO)
siRNA
mRNA
Segment by Application
Neuromuscular Diseases
hATTR
COVID-19
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid and Oligonucleotide Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.
The global Nucleic Acid and Oligonucleotide Therapeutics market was valued at US$ 12490 million in 2023 and is anticipated to reach US$ 16120 million by 2030, witnessing a CAGR of 3.7% during the forecast period 2024-2030.
North American market for Nucleic Acid and Oligonucleotide Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Nucleic Acid and Oligonucleotide Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Nucleic Acid and Oligonucleotide Therapeutics in Neuromuscular Diseases is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Nucleic Acid and Oligonucleotide Therapeutics include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Nucleic Acid and Oligonucleotide Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid and Oligonucleotide Therapeutics.
The Nucleic Acid and Oligonucleotide Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Nucleic Acid and Oligonucleotide Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleic Acid and Oligonucleotide Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Segment by Type
Antisense Oligonucleotides (ASO)
siRNA
mRNA
Segment by Application
Neuromuscular Diseases
hATTR
COVID-19
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid and Oligonucleotide Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antisense Oligonucleotides (ASO)
1.2.3 siRNA
1.2.4 mRNA
1.3 Market by Application
1.3.1 Global Nucleic Acid and Oligonucleotide Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Neuromuscular Diseases
1.3.3 hATTR
1.3.4 COVID-19
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleic Acid and Oligonucleotide Therapeutics Market Perspective (2019-2030)
2.2 Global Nucleic Acid and Oligonucleotide Therapeutics Growth Trends by Region
2.2.1 Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Nucleic Acid and Oligonucleotide Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Nucleic Acid and Oligonucleotide Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Nucleic Acid and Oligonucleotide Therapeutics Market Dynamics
2.3.1 Nucleic Acid and Oligonucleotide Therapeutics Industry Trends
2.3.2 Nucleic Acid and Oligonucleotide Therapeutics Market Drivers
2.3.3 Nucleic Acid and Oligonucleotide Therapeutics Market Challenges
2.3.4 Nucleic Acid and Oligonucleotide Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nucleic Acid and Oligonucleotide Therapeutics Players by Revenue
3.1.1 Global Top Nucleic Acid and Oligonucleotide Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Nucleic Acid and Oligonucleotide Therapeutics Revenue
3.4 Global Nucleic Acid and Oligonucleotide Therapeutics Market Concentration Ratio
3.4.1 Global Nucleic Acid and Oligonucleotide Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid and Oligonucleotide Therapeutics Revenue in 2023
3.5 Global Key Players of Nucleic Acid and Oligonucleotide Therapeutics Head office and Area Served
3.6 Global Key Players of Nucleic Acid and Oligonucleotide Therapeutics, Product and Application
3.7 Global Key Players of Nucleic Acid and Oligonucleotide Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Nucleic Acid and Oligonucleotide Therapeutics Breakdown Data by Type
4.1 Global Nucleic Acid and Oligonucleotide Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Nucleic Acid and Oligonucleotide Therapeutics Forecasted Market Size by Type (2025-2030)
5 Nucleic Acid and Oligonucleotide Therapeutics Breakdown Data by Application
5.1 Global Nucleic Acid and Oligonucleotide Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Nucleic Acid and Oligonucleotide Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Nucleic Acid and Oligonucleotide Therapeutics Market Size (2019-2030)
6.2 North America Nucleic Acid and Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024)
6.4 North America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size (2019-2030)
7.2 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024)
7.4 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size (2019-2030)
9.2 Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.1.4 Sarepta Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.1.5 Sarepta Therapeutics Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Details
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.2.4 Ionis Pharmaceuticals Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 Alnylam
11.3.1 Alnylam Company Details
11.3.2 Alnylam Business Overview
11.3.3 Alnylam Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.3.4 Alnylam Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.3.5 Alnylam Recent Development
11.4 Biogen
11.4.1 Biogen Company Details
11.4.2 Biogen Business Overview
11.4.3 Biogen Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.4.4 Biogen Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.4.5 Biogen Recent Development
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Details
11.5.2 Nippon Shinyaku Business Overview
11.5.3 Nippon Shinyaku Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.5.4 Nippon Shinyaku Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.5.5 Nippon Shinyaku Recent Development
11.6 Sobi
11.6.1 Sobi Company Details
11.6.2 Sobi Business Overview
11.6.3 Sobi Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.6.4 Sobi Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.6.5 Sobi Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.7.4 Novartis Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 BioNTech
11.8.1 BioNTech Company Details
11.8.2 BioNTech Business Overview
11.8.3 BioNTech Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.8.4 BioNTech Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.8.5 BioNTech Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.9.4 Pfizer Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Details
11.10.2 Moderna Therapeutics Business Overview
11.10.3 Moderna Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.10.4 Moderna Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.10.5 Moderna Therapeutics Recent Development
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Details
11.11.2 Jazz Pharmaceuticals Business Overview
11.11.3 Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.11.4 Jazz Pharmaceuticals Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.11.5 Jazz Pharmaceuticals Recent Development
11.12 CureVac
11.12.1 CureVac Company Details
11.12.2 CureVac Business Overview
11.12.3 CureVac Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.12.4 CureVac Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.12.5 CureVac Recent Development
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Details
11.13.2 Regulus Therapeutics Business Overview
11.13.3 Regulus Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.13.4 Regulus Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.13.5 Regulus Therapeutics Recent Development
11.14 ProQR
11.14.1 ProQR Company Details
11.14.2 ProQR Business Overview
11.14.3 ProQR Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.14.4 ProQR Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.14.5 ProQR Recent Development
11.15 Secarna
11.15.1 Secarna Company Details
11.15.2 Secarna Business Overview
11.15.3 Secarna Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.15.4 Secarna Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.15.5 Secarna Recent Development
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Details
11.16.2 MiNA Therapeutics Business Overview
11.16.3 MiNA Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.16.4 MiNA Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.16.5 MiNA Therapeutics Recent Development
11.17 Sylentis
11.17.1 Sylentis Company Details
11.17.2 Sylentis Business Overview
11.17.3 Sylentis Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.17.4 Sylentis Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.17.5 Sylentis Recent Development
11.18 Arrowhead
11.18.1 Arrowhead Company Details
11.18.2 Arrowhead Business Overview
11.18.3 Arrowhead Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.18.4 Arrowhead Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.18.5 Arrowhead Recent Development
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Details
11.19.2 Silence Therapeutics Business Overview
11.19.3 Silence Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.19.4 Silence Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.19.5 Silence Therapeutics Recent Development
11.20 Dicerna
11.20.1 Dicerna Company Details
11.20.2 Dicerna Business Overview
11.20.3 Dicerna Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.20.4 Dicerna Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
11.20.5 Dicerna Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Antisense Oligonucleotides (ASO)
Table 3. Key Players of siRNA
Table 4. Key Players of mRNA
Table 5. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Region (2019-2024)
Table 9. Global Nucleic Acid and Oligonucleotide Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Region (2025-2030)
Table 11. Nucleic Acid and Oligonucleotide Therapeutics Market Trends
Table 12. Nucleic Acid and Oligonucleotide Therapeutics Market Drivers
Table 13. Nucleic Acid and Oligonucleotide Therapeutics Market Challenges
Table 14. Nucleic Acid and Oligonucleotide Therapeutics Market Restraints
Table 15. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Players (2019-2024)
Table 17. Global Top Nucleic Acid and Oligonucleotide Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid and Oligonucleotide Therapeutics as of 2023)
Table 18. Ranking of Global Top Nucleic Acid and Oligonucleotide Therapeutics Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Nucleic Acid and Oligonucleotide Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 20. Global Key Players of Nucleic Acid and Oligonucleotide Therapeutics, Headquarters and Area Served
Table 21. Global Key Players of Nucleic Acid and Oligonucleotide Therapeutics, Product and Application
Table 22. Global Key Players of Nucleic Acid and Oligonucleotide Therapeutics, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Type (2019-2024)
Table 26. Global Nucleic Acid and Oligonucleotide Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Type (2025-2030)
Table 28. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Application (2019-2024)
Table 30. Global Nucleic Acid and Oligonucleotide Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Application (2025-2030)
Table 32. North America Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 47. Sarepta Therapeutics Company Details
Table 48. Sarepta Therapeutics Business Overview
Table 49. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product
Table 50. Sarepta Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 51. Sarepta Therapeutics Recent Development
Table 52. Ionis Pharmaceuticals Company Details
Table 53. Ionis Pharmaceuticals Business Overview
Table 54. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Product
Table 55. Ionis Pharmaceuticals Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 56. Ionis Pharmaceuticals Recent Development
Table 57. Alnylam Company Details
Table 58. Alnylam Business Overview
Table 59. Alnylam Nucleic Acid and Oligonucleotide Therapeutics Product
Table 60. Alnylam Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 61. Alnylam Recent Development
Table 62. Biogen Company Details
Table 63. Biogen Business Overview
Table 64. Biogen Nucleic Acid and Oligonucleotide Therapeutics Product
Table 65. Biogen Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 66. Biogen Recent Development
Table 67. Nippon Shinyaku Company Details
Table 68. Nippon Shinyaku Business Overview
Table 69. Nippon Shinyaku Nucleic Acid and Oligonucleotide Therapeutics Product
Table 70. Nippon Shinyaku Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 71. Nippon Shinyaku Recent Development
Table 72. Sobi Company Details
Table 73. Sobi Business Overview
Table 74. Sobi Nucleic Acid and Oligonucleotide Therapeutics Product
Table 75. Sobi Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 76. Sobi Recent Development
Table 77. Novartis Company Details
Table 78. Novartis Business Overview
Table 79. Novartis Nucleic Acid and Oligonucleotide Therapeutics Product
Table 80. Novartis Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 81. Novartis Recent Development
Table 82. BioNTech Company Details
Table 83. BioNTech Business Overview
Table 84. BioNTech Nucleic Acid and Oligonucleotide Therapeutics Product
Table 85. BioNTech Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 86. BioNTech Recent Development
Table 87. Pfizer Company Details
Table 88. Pfizer Business Overview
Table 89. Pfizer Nucleic Acid and Oligonucleotide Therapeutics Product
Table 90. Pfizer Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 91. Pfizer Recent Development
Table 92. Moderna Therapeutics Company Details
Table 93. Moderna Therapeutics Business Overview
Table 94. Moderna Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product
Table 95. Moderna Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 96. Moderna Therapeutics Recent Development
Table 97. Jazz Pharmaceuticals Company Details
Table 98. Jazz Pharmaceuticals Business Overview
Table 99. Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Product
Table 100. Jazz Pharmaceuticals Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 101. Jazz Pharmaceuticals Recent Development
Table 102. CureVac Company Details
Table 103. CureVac Business Overview
Table 104. CureVac Nucleic Acid and Oligonucleotide Therapeutics Product
Table 105. CureVac Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 106. CureVac Recent Development
Table 107. Regulus Therapeutics Company Details
Table 108. Regulus Therapeutics Business Overview
Table 109. Regulus Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product
Table 110. Regulus Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 111. Regulus Therapeutics Recent Development
Table 112. ProQR Company Details
Table 113. ProQR Business Overview
Table 114. ProQR Nucleic Acid and Oligonucleotide Therapeutics Product
Table 115. ProQR Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 116. ProQR Recent Development
Table 117. Secarna Company Details
Table 118. Secarna Business Overview
Table 119. Secarna Nucleic Acid and Oligonucleotide Therapeutics Product
Table 120. Secarna Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 121. Secarna Recent Development
Table 122. MiNA Therapeutics Company Details
Table 123. MiNA Therapeutics Business Overview
Table 124. MiNA Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product
Table 125. MiNA Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 126. MiNA Therapeutics Recent Development
Table 127. Sylentis Company Details
Table 128. Sylentis Business Overview
Table 129. Sylentis Nucleic Acid and Oligonucleotide Therapeutics Product
Table 130. Sylentis Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 131. Sylentis Recent Development
Table 132. Arrowhead Company Details
Table 133. Arrowhead Business Overview
Table 134. Arrowhead Nucleic Acid and Oligonucleotide Therapeutics Product
Table 135. Arrowhead Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 136. Arrowhead Recent Development
Table 137. Silence Therapeutics Company Details
Table 138. Silence Therapeutics Business Overview
Table 139. Silence Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product
Table 140. Silence Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 141. Silence Therapeutics Recent Development
Table 142. Dicerna Company Details
Table 143. Dicerna Business Overview
Table 144. Dicerna Nucleic Acid and Oligonucleotide Therapeutics Product
Table 145. Dicerna Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 146. Dicerna Recent Development
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
Table 150. Authors List of This Report
List of Figures
Figure 1. Nucleic Acid and Oligonucleotide Therapeutics Picture
Figure 2. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Type: 2023 VS 2030
Figure 4. Antisense Oligonucleotides (ASO) Features
Figure 5. siRNA Features
Figure 6. mRNA Features
Figure 7. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (2024-2030) & (US$ Million)
Figure 8. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Application: 2023 VS 2030
Figure 9. Neuromuscular Diseases Case Studies
Figure 10. hATTR Case Studies
Figure 11. COVID-19 Case Studies
Figure 12. Other Case Studies
Figure 13. Nucleic Acid and Oligonucleotide Therapeutics Report Years Considered
Figure 14. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Region: 2023 VS 2030
Figure 17. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Players in 2023
Figure 18. Global Top Nucleic Acid and Oligonucleotide Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid and Oligonucleotide Therapeutics as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Nucleic Acid and Oligonucleotide Therapeutics Revenue in 2023
Figure 20. North America Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Nucleic Acid and Oligonucleotide Therapeutics Market Share by Country (2019-2030)
Figure 22. United States Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Share by Country (2019-2030)
Figure 26. Germany Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Share by Region (2019-2030)
Figure 34. China Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Share by Country (2019-2030)
Figure 42. Mexico Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Share by Country (2019-2030)
Figure 46. Turkey Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. UAE Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Sarepta Therapeutics Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 50. Ionis Pharmaceuticals Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 51. Alnylam Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 52. Biogen Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 53. Nippon Shinyaku Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 54. Sobi Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 55. Novartis Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 56. BioNTech Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 57. Pfizer Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 58. Moderna Therapeutics Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 59. Jazz Pharmaceuticals Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 60. CureVac Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 61. Regulus Therapeutics Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 62. ProQR Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 63. Secarna Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 64. MiNA Therapeutics Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 65. Sylentis Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 66. Arrowhead Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 67. Silence Therapeutics Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 68. Dicerna Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2019-2024)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
